Loading...
XSTO
2CUREX
Market cap4mUSD
Jul 10, Last price  
1.87SEK
1D
-1.06%
1Q
79.81%
IPO
-72.70%
Name

2cureX AB

Chart & Performance

D1W1MN
XSTO:2CUREX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
4.44%
Shrs. gr., 5y
13.03%
Rev. gr., 5y
-54.18%
Revenues
0k
2,234,7101,347,05647,0007,675,00011,982,00015,391,0007,391,00090,000155,00000
Net income
-3m
L-36.77%
00-3,136,000-7,264,000-7,933,000-7,320,000-18,937,000-29,770,000-32,518,000-4,128,000-2,610,000
CFO
-5m
L-85.18%
01,206,538-4,348,0001,150,000-7,864,000-11,694,000-18,426,000-27,984,000-31,222,000-4,626,000
Dividend
Jun 27, 20250.084 SEK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Based in Copenhagen, Denmark, 2cureX AB (publ) is a European medtech firm established in 2006. The company's core offering is IndiTreat, an in-vitro diagnostic test designed to forecast how cancer patients will respond to or resist various drug treatments, thereby guiding clinicians in selecting the most effective therapy. Additionally, 2cureX is actively advancing IndiTreat through clinical programs targeting a range of cancers, including breast, colorectal, ovarian, and pancreatic types.
URL
https://www.2curex.com/
IPO date
Nov 24, 2017
Employees
14
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT